Monopar Therapeutics (MNPR)
D
Pipeline Grade
Financial Position (from SEC Filings)
$5.7M
Cash & Equivalents
$3.5M
Quarterly Burn Rate
5 mo
Est. Cash Runway
$714M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-12-01 | Phase1 Readout | — |
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06337084 | Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors | PHASE1 | Recruiting | 12 |
| NCT06617169 | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors | PHASE1 | Recruiting | 12 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.